Gale C P, Manda S O M, Weston C F, Birkhead J S, Batin P D, Hall A S
Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics Health and Therapeutics, University of Leeds, Clarendon Way, West Yorkshire, Leeds LS2 9JT, UK.
Heart. 2009 Mar;95(3):221-7. doi: 10.1136/hrt.2008.144022. Epub 2008 May 8.
To compare the discriminative performance of the PURSUIT, GUSTO-1, GRACE, SRI and EMMACE risk models, assess their performance among risk supergroups and evaluate the EMMACE risk model over the wider spectrum of acute coronary syndrome (ACS).
Observational study of a national registry.
All acute hospitals in England and Wales.
100 686 cases of ACS between 2003 and 2005.
Model performance (C-index) in predicting the likelihood of death over the time period for which they were designed. The C-index, or area under the receiver-operating curve, range 0-1, is a measure of the discriminative performance of a model.
The C-indexes were: PURSUIT C-index 0.79 (95% confidence interval 0.78 to 0.80); GUSTO-1 0.80 (0.79 to 0.81); GRACE in-hospital 0.80 (0.80 to 0.81); GRACE 6-month 0.80 (0.79 to 0.80); SRI 0.79 (0.78 to 0.80); and EMMACE 0.78 (0.77 to 0.78). EMMACE maintained its ability to discriminate 30-day mortality throughout different ACS diagnoses. Recalibration of the model offered no notable improvement in performance over the original risk equation. For all models the discriminative performance was reduced in patients with diabetes, chronic renal failure or angina.
The five ACS risk models maintained their discriminative performance in a large unselected English and Welsh ACS population, but performed less well in higher-risk supergroups. Simpler risk models had comparable performance to more complex risk models. The EMMACE risk score performed well across the wider spectrum of ACS diagnoses.
比较PURSUIT、GUSTO-1、GRACE、SRI和EMMACE风险模型的鉴别性能,评估它们在风险超群中的表现,并在更广泛的急性冠状动脉综合征(ACS)范围内评估EMMACE风险模型。
对国家登记处的观察性研究。
英格兰和威尔士的所有急症医院。
2003年至2005年间的100686例ACS病例。
模型在其设计时间段内预测死亡可能性的性能(C指数)。C指数,即受试者工作特征曲线下面积,范围为0至1,是模型鉴别性能的一种度量。
C指数分别为:PURSUIT C指数0.79(95%置信区间0.78至0.80);GUSTO-1 0.80(0.79至0.81);GRACE住院时0.80(0.80至0.81);GRACE 6个月时0.80(0.79至0.80);SRI 0.79(0.78至0.80);EMMACE 0.78(0.77至0.78)。EMMACE在不同的ACS诊断中均保持了区分30天死亡率的能力。对模型进行重新校准后,其性能相比原始风险方程并无显著改善。对于所有模型,糖尿病、慢性肾衰竭或心绞痛患者的鉴别性能均有所降低。
这五个ACS风险模型在未经过筛选的大量英格兰和威尔士ACS人群中保持了其鉴别性能,但在高风险超群中表现较差。较简单的风险模型与更复杂的风险模型具有相当的性能。EMMACE风险评分在更广泛的ACS诊断范围内表现良好。